The World In A Grain of Sand by KdT Ventures
Subscribe
Sign in
Home
Archive
About
New
Top
Podcast: Amylyx Pharmaceuticals
a neuro biotech founded in the dorm room of two scrappy Brown undergrads
Apr 19
•
Rima Chakrabarti
,
Mack
, and
Patrick Malone
3
Share this post
Podcast: Amylyx Pharmaceuticals
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
March 2023
Overscienced but Underfunded: Research Triangle, NC (Durham, Raleigh, Chapel Hill)
Impactful science and technology can be invented anywhere
Mar 29
•
Phil Grayeski
,
Ketan Yerneni
,
Patrick Malone
,
Anirudh Sudarshan
, and
Dalton Hughes, PhD
5
Share this post
Overscienced but Underfunded: Research Triangle, NC (Durham, Raleigh, Chapel Hill)
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
September 2022
Expanding the Drug Delivery Toolbox
Today our ability to treat many diseases is limited only by our ability to effectively deliver genetic medicines. Patients treated with genetic…
Sep 15, 2022
1
Share this post
Expanding the Drug Delivery Toolbox
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
May 2022
State of the Market: The Goalposts
Before I start, let me get two things out of the way. First, in no way am I the caller of market tops and bottoms — and that’s not the intent of this…
May 9, 2022
1
Share this post
State of the Market: The Goalposts
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
The Bioproduction Battle
The globalization that began during the 1990s and flourished into this millennia reshaped aspects of our lives in ways we are only now appreciating…
May 2, 2022
Share this post
The Bioproduction Battle
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
February 2022
How health insurance DAOs can break up RWD silos
KdT has recently been exploring alternative data sharing incentive structures, since as a firm we believe the greatest advancements in science and…
Feb 14, 2022
Share this post
How health insurance DAOs can break up RWD silos
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
August 2021
Zymergen: A Cautionary Tale
As we continue to digest the news from Zymergen and its reverberations across the Synthetic Biology ecosystem, we wanted to take a moment to reflect in…
Aug 5, 2021
Share this post
Zymergen: A Cautionary Tale
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
May 2021
The World in a Grain of Sand
Content is king (or so my kids tell me). We would like to be able to say that we have a grand plan in mind behind launching curated content at KdT…
May 13, 2021
Share this post
The World in a Grain of Sand
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
March 2021
What $50M in New Capital Means for Entrepreneurs
Today we’re announcing the closing of our $50M Fund II for KdT Ventures. With the announcement, one important aspect is obvious: with this fresh…
Mar 23, 2021
Share this post
What $50M in New Capital Means for Entrepreneurs
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
January 2021
Partnering and Focus
N.B.- As a reminder, we are a seed-stage firm so our views relate to companies at that seed stage. Many early stage founders balance seeking commercial…
Jan 26, 2021
Share this post
Partnering and Focus
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
The Golden Age of Microfluidics?
Lately, it feels like a disproportionately large number of companies we have seen at KdT deploy or manipulate microfluidic technology of various flavors…
Jan 6, 2021
•
Patrick Malone
Share this post
The Golden Age of Microfluidics?
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
June 2020
How Platforms Can Think Intelligently About Early Deal Structure
Before jumping in headfirst, it’s important to acknowledge relevant qualifiers: KdT Ventures is a seed stage venture firm and thus this article relates…
Jun 29, 2020
•
Patrick Malone
Share this post
How Platforms Can Think Intelligently About Early Deal Structure
kdtvc.substack.com
Copy link
Facebook
Email
Notes
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
